Genovis AB (publ.) (GENO.ST)
GENO.ST Stock Price Chart
Explore Genovis AB (publ.) interactive price chart. Choose custom timeframes to analyze GENO.ST price movements and trends.
GENO.ST Company Profile
Discover essential business fundamentals and corporate details for Genovis AB (publ.) (GENO.ST) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Jun 2008
Employees
32.00
Website
https://www.genovis.comCEO
Fredrik Olsson
Description
Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.
GENO.ST Financial Timeline
Browse a chronological timeline of Genovis AB (publ.) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 May 2026
Upcoming earnings on 12 Feb 2026
Upcoming earnings on 7 Nov 2025
Earnings released on 12 Aug 2025
EPS came in at kr 0.08 falling short of the estimated kr 0.11 by -25.56%, while revenue for the quarter reached kr 28.87M , missing expectations by -12.60%.
Earnings released on 21 May 2025
EPS came in at kr 0.05 falling short of the estimated kr 0.10 by -50.00%, while revenue for the quarter reached kr 32.29M , beating expectations by +7.52%.
Earnings released on 14 Feb 2025
EPS came in at kr 0.07 surpassing the estimated kr 0.06 by +16.67%, while revenue for the quarter reached kr 27.94M , missing expectations by -10.46%.
Earnings released on 8 Nov 2024
EPS came in at kr 0.21 surpassing the estimated kr 0.09 by +133.33%, while revenue for the quarter reached kr 32.90M , beating expectations by +15.22%.
Earnings released on 20 Aug 2024
EPS came in at kr 0.03 falling short of the estimated kr 0.11 by -72.73%, while revenue for the quarter reached kr 29.47M , missing expectations by -9.97%.
Earnings released on 15 May 2024
EPS came in at kr 0.19 surpassing the estimated kr 0.14 by +35.71%, while revenue for the quarter reached kr 40.06M , beating expectations by +7.20%.
Earnings released on 15 Feb 2024
EPS came in at -kr 0.01 falling short of the estimated kr 0.32 by -103.17%, while revenue for the quarter reached kr 27.31M , missing expectations by -16.24%.
Earnings released on 15 Nov 2023
EPS came in at kr 0.05 falling short of the estimated kr 0.86 by -94.15%, while revenue for the quarter reached kr 30.19M , missing expectations by -1.03%.
Earnings released on 24 Aug 2023
EPS came in at kr 0.23 surpassing the estimated kr 0.10 by +130.00%, while revenue for the quarter reached kr 31.47M , missing expectations by -29.12%.
Earnings released on 16 May 2023
EPS came in at kr 0.67 surpassing the estimated kr 0.60 by +11.67%, while revenue for the quarter reached kr 72.35M , beating expectations by +1.04%.
Earnings released on 15 Feb 2023
EPS came in at -kr 0.11 falling short of the estimated kr 0.10 by -210.00%, while revenue for the quarter reached kr 16.48M , missing expectations by -41.77%.
Earnings released on 15 Nov 2022
EPS came in at kr 0.09 , while revenue for the quarter reached kr 26.97M , beating expectations by +9.63%.
Earnings released on 12 Aug 2022
EPS came in at kr 0.01 falling short of the estimated kr 0.10 by -90.00%, while revenue for the quarter reached kr 24.98M , beating expectations by +13.55%.
Earnings released on 27 Apr 2022
EPS came in at kr 0.20 , while revenue for the quarter reached kr 33.96M .
Earnings released on 8 Feb 2022
EPS came in at kr 0.34 surpassing the estimated kr 0.28 by +21.14%, while revenue for the quarter reached kr 38.21M , missing expectations by -24.34%.
Earnings released on 12 Nov 2021
EPS came in at kr 0.01 , while revenue for the quarter reached kr 17.64M .
Earnings released on 12 Aug 2021
EPS came in at kr 0.02 , while revenue for the quarter reached kr 21.25M .
Earnings released on 29 Apr 2021
EPS came in at kr 0.01 , while revenue for the quarter reached kr 15.92M .
Earnings released on 11 Feb 2021
EPS came in at kr 0.13 , while revenue for the quarter reached kr 19.00M .
Earnings released on 5 Nov 2020
EPS came in at kr 0.02 , while revenue for the quarter reached kr 14.49M .
GENO.ST Stock Performance
Access detailed GENO.ST performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.